ClinicalTrials.gg
CompletedNCT00885352Updated May 23, 2017Results posted

Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

A Phase 3 interventional study of Sitagliptin and Comparator: Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
313
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
53rd of 197
313 · median 102
Started
2009
with 11 others
Phase 3
74 of 198
none open now
Registered
67th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 53rd largest by enrollment of the 197 interventional ones that give a count, is one of 12 that started in 2009, is one of 74 in phase 3, and was the 67th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will examine the safety and efficacy of the addition of sitagliptin (MK-0431) compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic control who are taking pioglitazone and metformin.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • has type 2 diabetes and is at least 18 years of age and no older than 78 years of age
  • is male or is a female who is unlikely to conceive children
  • is on stable doses of a peroxisome proliferator-activated receptor gamma agonist and metformin OR metformin and a sulfonylurea agent

Exclusion criteria

Exclusion Criteria:

  • has type 1 diabetes
  • has taken a dipeptidyl peptidase (DPP-4) inhibitor or a glucagon-like peptide-1 (GLP-1) analogue
  • is on a weight loss program that is not in the maintenance phase or has started a weight loss medication within 8 weeks of screening
  • has had surgery within 30 days of screening or has major surgery planned during the study
  • is on or is likely to require treatment with for more than 2 weeks
  • has a history of active liver disease, including or C, cirrhosis, or gallbladder disease
  • is (HIV) positive
  • has congestive heart failure, or has had new or worsening symptoms of coronary heart disease within 3 months prior to screening
  • has had acute coronary syndrome, coronary artery intervention, or stroke within 3 months of screening
  • has severe active peripheral vascular disease
  • has a history of cancer or blood disorder
  • is pregnant or breast feeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
313 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin 100 mg tablet orally once daily for 26 weeks.

    Drug: Sitagliptin · Drug: Pioglitazone · Drug: Metformin · Drug: Glipizide

  • Placebo comparator
    Placebo

    Placebo to sitagliptin orally once daily for 26 weeks.

    Drug: Comparator: Placebo · Drug: Pioglitazone · Drug: Metformin · Drug: Glipizide

Interventions

  • Sitagliptin 100 mg tablet orally once daily for 26 weeks.

    Also known as: Januvia, MK-0431

  • DrugComparator: Placebo

    Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.

  • Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.

    Also known as: Actos

  • Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.

    Also known as: Glucophage

  • Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.

    Also known as: Glucotrol

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (A1C) at Week 26

    Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26

    Change from baseline reflects the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26

    Change from baseline reflects the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

07

Results

Posted Feb 1, 2012

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinPlacebo
Started157156
Completed149136
Not completed820
Withdrew: Adverse event23
Withdrew: Lost to follow-up22
Withdrew: Physician decision03
Withdrew: Protocol violation02
Withdrew: Withdrawal by subject15
Withdrew: Contradiction to study medication02
Withdrew: Excluded medication22
Withdrew: Lab abnormalities11

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (A1C) at Week 26

Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percent of glycosylated hemoglobin
Change From Baseline in Hemoglobin A1c (A1C) at Week 26
Percent of glycosylated hemoglobinSitagliptinPlacebo
Change From Baseline in Hemoglobin A1c (A1C) at Week 26-1.15 ± 0.93-0.40 ± 1.00
SecondaryChange From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26

Change from baseline reflects the Week 26 value minus the baseline value.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26
mg/dLSitagliptinPlacebo
Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26-54.4 ± 64.4-14.7 ± 59.6
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 26

Change from baseline reflects the Week 26 value minus the baseline value.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
mg/dLSitagliptinPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26-20.3 ± 49.5-2.8 ± 41.6

Adverse events

Collected over Weeks 0 to 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg—3/157 (1.9%)22/157 (14%)
Placebo—6/156 (3.8%)20/156 (12.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventSitagliptin 100 mgPlacebo
Cardiac arrestCardiac disorders0/1571/156
Gastric ulcer haemorrhageGastrointestinal disorders0/1571/156
PeritonitisGastrointestinal disorders0/1571/156
AppendicitisInfections and infestations0/1571/156
Dengue feverInfections and infestations0/1571/156
Cartilage injuryInjury, poisoning and procedural complications0/1571/156
Patella fractureInjury, poisoning and procedural complications0/1571/156
OsteoarthritisMusculoskeletal and connective tissue disorders0/1571/156
Chest discomfortGeneral disorders1/1570/156
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1570/156
Most frequent other events
Most frequent other events
EventSitagliptin 100 mgPlacebo
Upper respiratory tract infectionInfections and infestations13/15714/156
HypoglycaemiaMetabolism and nutrition disorders10/1577/156

Baseline characteristics

Age, Continuous
Age, Continuous(years)SitagliptinPlaceboTotal
Mean55.7 ± 8.756.4 ± 9.456.1 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlaceboTotal
Female6058118
Male9798195
Hemoglobin A1c (A1C)
Hemoglobin A1c (A1C)(Percent of gylcosylated hemoglobin)SitagliptinPlaceboTotal
Mean8.8 ± 1.08.7 ± 1.08.7 ± 1.0
2-hour post-meal glucose (PMG)
2-hour post-meal glucose (PMG)(mg/dL)SitagliptinPlaceboTotal
Mean275.5 ± 66.4266.0 ± 62.4270.8 ± 64.5
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mg/dL)SitagliptinPlaceboTotal
Mean179.3 ± 44.3173.6 ± 38.9176.5 ± 41.7
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Fonseca V, Staels B, Morgan JD 2nd, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complications. 2013 Mar-Apr;27(2):177-83. doi: 10.1016/j.jdiacomp.2012.09.007. Epub 2012 Oct 30. PubMed 23116881 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2009 to primary completion in Nov 2010, 18 months.

Results were first posted in Feb 2012, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2009
First posted
Apr 21, 2009
StartActual
Apr 15, 2009
Primary completionActual
Nov 10, 2010
CompletionActual
Nov 10, 2010
Results first posted
Feb 1, 2012
Last update
May 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00885352
Responsible party
Sponsor
First posted
Apr 21, 2009
Start date
Apr 15, 2009
Primary completion
Nov 10, 2010
Completion
Nov 10, 2010
Results posted
Feb 1, 2012
Last update
May 23, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion